A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma ; volume:23 ; number:1 ; day:8 ; month:7 ; year:2023 ; pages:1-10 ; date:12.2023
BMC cancer ; 23, Heft 1 (8.7.2023), 1-10, 12.2023
- Creator
-
Tansir, Ghazal
Rastogi, Sameer
Kumar, Akash
Barwad, Adarsh
Mridha, Asit R.
Dhamija, Ekta
Shamim, Shamim A.
Bhatnagar, Sushma
Bhoriwal, Sandeep
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-11099-4
- URN
-
urn:nbn:de:101:1-2023101208533789877132
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tansir, Ghazal
- Rastogi, Sameer
- Kumar, Akash
- Barwad, Adarsh
- Mridha, Asit R.
- Dhamija, Ekta
- Shamim, Shamim A.
- Bhatnagar, Sushma
- Bhoriwal, Sandeep
- SpringerLink (Online service)
Other Objects (12)
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer